Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, reposted from World Federation of Hemophilia on LinkedIn:
”I’m proud to share this important milestone: Takeda has renewed its 5-year agreement with the WFH and WFH_USA—furthering our support for the WFH Humanitarian Aid Program!
Together with other partners, we are working to expand access, drive equity, and change lives for people living with inherited bleeding disorders globally.”
Quoting World Federation of Hemophilia‘s post:
”The WFH and WFH USA are pleased to announce that Takeda has signed a 5-year agreement renewal with the WFH Humanitarian Aid Program from 2026 to 2030!
The agreement is for the donation of treatment product, as well as a financial commitment to cover it’s handling, storage and shipping. Learn more.”
Stay updated with Hemostasis Today.
-
Dec 11, 2025, 16:18Caitlin Raymond’s Commentary on Artificial Intelligence in Transfusion Medicine is Out!
-
Dec 11, 2025, 15:05Kristof Vercruysse on ”First in Human” Presented at ASH25
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report
-
Dec 11, 2025, 12:12Zoey Becker: CSL Proves Efficacy of Hemophilia B Gene Therapy Hemgenix Holds up After 5 Years